|
ES2203782T3
(es)
|
1996-01-17 |
2004-04-16 |
Imperial College Innovations Limited |
Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
|
|
US6872518B2
(en)
|
1997-09-22 |
2005-03-29 |
University Of Rochester |
Methods for selecting polynucleotides encoding T cell epitopes
|
|
PT1103564E
(pt)
|
1998-07-31 |
2009-03-13 |
Int Inst Cancer Immunology Inc |
Antigénios de cancro com base no produto do gene supressor de tumor wt1
|
|
US6407063B1
(en)
*
|
1998-10-02 |
2002-06-18 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
|
EP1117679B9
(en)
*
|
1998-10-02 |
2010-07-07 |
Ludwig Institute For Cancer Research |
Tumor antigens and ctl clones isolated by a novel procedure
|
|
GB9823897D0
(en)
|
1998-11-02 |
1998-12-30 |
Imp College Innovations Ltd |
Immunotherapeutic methods and molecules
|
|
DE69839970D1
(de)
*
|
1998-11-10 |
2008-10-16 |
Univ Rochester |
Methoden zu herstellung von genbanken
|
|
JP2003525862A
(ja)
|
1999-01-27 |
2003-09-02 |
ザ ユニヴァーシティー オブ サウス フロリダ |
ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
|
|
EP1118661A1
(en)
*
|
2000-01-13 |
2001-07-25 |
Het Nederlands Kanker Instituut |
T cell receptor libraries
|
|
US20030119185A1
(en)
*
|
2000-02-24 |
2003-06-26 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US6797514B2
(en)
*
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US20030235908A1
(en)
*
|
2000-02-24 |
2003-12-25 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
|
US7572631B2
(en)
*
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
WO2001072995A2
(en)
|
2000-03-28 |
2001-10-04 |
University Of Rochester |
Methods of producing a library and methods of selecting polynucletides
|
|
AU2001259744A1
(en)
*
|
2000-05-11 |
2001-11-20 |
Baylor Research Institute |
Compositions and methods for producing antigen-presenting cells
|
|
WO2001089539A2
(en)
*
|
2000-05-25 |
2001-11-29 |
Xcyte Therapies, Inc. |
Methods for restoring or enhancing t-cell immune surveillance following naturally or artifically induced immunosuppression
|
|
DE10112851C1
(de)
|
2001-03-16 |
2002-10-10 |
Gsf Forschungszentrum Umwelt |
Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
|
|
WO2003033520A2
(en)
*
|
2001-09-24 |
2003-04-24 |
University Of Pittburgh Of The Commonwealth System Of Higher Education |
Anticancer vaccine and diganostic methods and reagents
|
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US7638122B2
(en)
|
2003-03-07 |
2009-12-29 |
University Of South Florida |
Stat3 antagonists and their use as vaccines against cancer
|
|
JP2006524991A
(ja)
*
|
2003-05-08 |
2006-11-09 |
エクサイト セラピーズ インコーポレーティッド |
抗原特異的ｔ細胞の作製および単離の方法
|
|
WO2005030251A1
(en)
*
|
2003-09-22 |
2005-04-07 |
Xcyte Therapies, Inc. |
Compositions and methods to accelerate hematologic recovery
|
|
DE10344799A1
(de)
|
2003-09-26 |
2005-04-14 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
DE102004023187A1
(de)
|
2004-05-11 |
2005-12-01 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
US7915036B2
(en)
*
|
2004-09-13 |
2011-03-29 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Compositions comprising T cell receptors and methods of use thereof
|
|
ES2319286T3
(es)
|
2004-10-02 |
2009-05-06 |
Immatics Biotechnologies Gmbh |
Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
|
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
|
DE102005013846A1
(de)
|
2005-03-24 |
2006-10-05 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
ATE512160T1
(de)
|
2005-04-26 |
2011-06-15 |
Immatics Biotechnologies Gmbh |
T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
|
|
ATE484578T1
(de)
*
|
2005-08-05 |
2010-10-15 |
Helmholtz Zentrum Muenchen |
Erzeugung allorestriktiver spezifischer t-zellen
|
|
EP1806359B1
(en)
|
2005-09-05 |
2010-03-17 |
Immatics Biotechnologies GmbH |
Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
|
|
SI1760089T1
(sl)
|
2005-09-05 |
2009-12-31 |
Immatics Biotechnologies Gmbh |
S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
|
|
EP1951281B1
(en)
|
2005-10-17 |
2015-04-15 |
Sloan Kettering Institute For Cancer Research |
Wt1 hla class ii-binding peptides and compositions and methods comprising same
|
|
US9265816B2
(en)
|
2006-04-10 |
2016-02-23 |
Sloan Kettering Institute For Cancer Research |
Immunogenic WT-1 peptides and methods of use thereof
|
|
US20080131415A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
EP1932537A1
(en)
*
|
2006-12-12 |
2008-06-18 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Expression of transgenic T cell receptors in LAK-T cells
|
|
EA018456B1
(ru)
|
2007-07-27 |
2013-08-30 |
Имматикс Байотекнолоджиз Гмбх |
Новые иммуногенные эпитопы для иммунотерапии
|
|
MX2010001086A
(es)
|
2007-07-27 |
2010-04-09 |
Immatics Biotechnologies Gmbh |
Nueva inmunoterapia contra tumores neuronales y cerebrales.
|
|
RS54374B1
(sr)
|
2008-03-27 |
2016-04-28 |
Immatics Biotechnologies Gmbh |
Nova imunoterapija protiv tumora nervnih ćelija i mozga
|
|
SI2119726T2
(en)
|
2008-05-14 |
2018-03-30 |
Immatics Biotechnologies Gmbh |
New and powerful Class II MHC peptides derived from survivin and neurocane
|
|
WO2010011994A2
(en)
|
2008-07-25 |
2010-01-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polypeptides and uses thereof
|
|
PT2172211E
(pt)
|
2008-10-01 |
2015-03-09 |
Immatics Biotechnologies Gmbh |
Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
|
|
DK2352756T3
(da)
|
2008-11-24 |
2012-12-03 |
Helmholtz Zentrum Muenchen |
Højaffin T-cellereceptor og anvendelse af denne
|
|
US8586359B2
(en)
*
|
2009-07-28 |
2013-11-19 |
Promising Furture, LLC |
Compositions and methods of preparing alloreactive cytotoxic T cells
|
|
GB0917094D0
(en)
|
2009-09-29 |
2009-11-11 |
Ucl Biomedica Plc |
T-cell receptor
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
GB201019331D0
(en)
|
2010-03-19 |
2010-12-29 |
Immatics Biotechnologies Gmbh |
Methods for the diagnosis and treatment of cancer based on AVL9
|
|
EP2802347B1
(en)
|
2012-01-13 |
2019-01-09 |
Memorial Sloan Kettering Cancer Center |
Immunogenic wt-1 peptides and methods of use thereof
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
CA2898099C
(en)
|
2013-01-15 |
2025-09-16 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 Peptides and Their Methods of Use
|
|
TWI777196B
(zh)
|
2013-08-05 |
2022-09-11 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（五）
|
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
|
EP3172325B1
(en)
|
2014-07-22 |
2023-06-28 |
The University of Notre Dame du Lac |
Molecular constructs and uses thereof
|
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
|
LT3545965T
(lt)
|
2014-12-23 |
2021-09-10 |
Immatics Biotechnologies Gmbh |
Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
|
|
PL3388075T3
(pl)
|
2015-03-27 |
2023-12-11 |
Immatics Biotechnologies Gmbh |
Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów
|
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
|
HRP20202019T1
(hr)
|
2015-07-01 |
2021-04-30 |
Immatics Biotechnologies Gmbh |
Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
CN113880938B
(zh)
|
2015-07-06 |
2025-09-05 |
伊玛提克斯生物技术有限公司 |
用于食管癌和其他癌症免疫治疗的新型肽和肽组合物
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
|
IL302705A
(en)
|
2016-03-01 |
2023-07-01 |
Immatics Biotechnologies Gmbh |
Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
|
|
GB201603987D0
(en)
|
2016-03-08 |
2016-04-20 |
Immatics Biotechnologies Gmbh |
Uterine cancer treatments
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
MA44605A
(fr)
|
2016-04-06 |
2019-02-13 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers
|
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
|
WO2018138257A1
(en)
|
2017-01-27 |
2018-08-02 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
EA201992416A1
(ru)
|
2017-04-10 |
2020-02-25 |
Имматикс Байотекнолоджиз Гмбх |
Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
|
|
US11427614B2
(en)
|
2017-04-10 |
2022-08-30 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
|
EP3725327A3
(en)
|
2017-04-10 |
2021-01-20 |
Immatics Biotechnologies GmbH |
Peptides and combination thereof for use in the immunotherapy against cancers
|
|
US10800823B2
(en)
|
2017-07-07 |
2020-10-13 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
|
|
KR20250007011A
(ko)
|
2017-07-07 |
2025-01-13 |
이매틱스 바이오테크놀로지스 게엠베하 |
Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
|
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
|
EP3796923A4
(en)
*
|
2018-05-18 |
2022-03-09 |
Children's National Medical Center |
Improved targeted t-cell therapy
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
|
TW202028224A
(zh)
|
2018-09-17 |
2020-08-01 |
德商英麥提克生物技術股份有限公司 |
B*44限制肽在抗癌免疫治療的用途和相關方法
|
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
|
CN110408657B
(zh)
*
|
2018-09-30 |
2021-03-16 |
北京鼎成肽源生物技术有限公司 |
一种afft1细胞的构建方法
|
|
CN109294995B
(zh)
*
|
2018-09-30 |
2020-08-04 |
北京鼎成肽源生物技术有限公司 |
一种rfft1细胞
|
|
EP3894011B1
(en)
|
2018-12-11 |
2025-09-17 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
|
WO2020185628A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Cd40l compositions and methods for tunable regulation
|
|
WO2020185632A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
|
EP3983537A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
EP3983538A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
US11058725B2
(en)
|
2019-09-10 |
2021-07-13 |
Obsidian Therapeutics, Inc. |
CA2 compositions and methods for tunable regulation
|
|
BR112022013355A2
(pt)
|
2020-01-08 |
2022-09-20 |
Obsidian Therapeutics Inc |
Célula modificada, molécula de ácido nucleico, vetor, primeiro polinucleotídeo e segundo polinucleotídeo, método de produção de uma célula modificada, métodos para tratar ou prevenir uma doença em um sujeito em necessidade, para introduzir uma célula modificada, para modificar geneticamente uma ou mais células, e, sistema para a expressão sintonizável
|
|
JP2023525423A
(ja)
|
2020-01-15 |
2023-06-16 |
イマティクス バイオテクノロジーズ ゲーエムベーハー |
Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
|
|
EP4168053A1
(en)
|
2020-06-22 |
2023-04-26 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of cas nucleases
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的ｈｌａ展示肽
|
|
WO2022184805A1
(en)
|
2021-03-03 |
2022-09-09 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
|
|
IL308257A
(en)
|
2021-05-05 |
2024-01-01 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins that uniquely bind PRAME
|
|
TW202321277A
(zh)
|
2021-07-27 |
2023-06-01 |
德商英麥提克生物技術股份有限公司 |
特異性結合ｃｔ４５之抗原結合蛋白
|
|
WO2025021979A1
(en)
|
2023-07-27 |
2025-01-30 |
Immatics Biotechnologies Gmbh |
Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
|
|
WO2025040598A2
(en)
|
2023-08-18 |
2025-02-27 |
Immatics Biotechnologies Gmbh |
Peptides displayed by mhc for use in immunotherapy against different types of cancer
|